

LITERATURA

- Ahluwalia B, Moraes L, Magnusson MK, Öhman L. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. *Scand J Gastroenterol* 2018; 53: 379–389.
- Mináriková P. Současné možnosti medikamentózní léčby idiopatických střevních zánětů. *Medicína po promoci* 2019; 3: 201–204.
- Douda T. Fertilita, gravidita a kojení u nemocných s idiopatickými střevními záněty. *Remedia* 2017; 27: 384–388.
- Jarkovský J, Benešová K, Hejduk K, et al. Epidemiology, hospitalization and migration of patients with IBD under specialized care in the Czech Republic. *Gastroent Hepatol* 2017; 71: 501–509.
- Burisch J, Pedersen N, Cučkovič-Čavka S, et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. *Gut* 2014; 63: 588–597.
- Woude CJ, Ardizzone S, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. *J Crohns Colitis*. 2015; 9(2): 107–124.
- Lukáš M. Obecné principy biologické léčby u IBD. In: Pavelka K et al (eds). *Biologická léčba zánětlivých autoimunitních onemocnění*. Praha: Grada 2014: 253–264.
- Bortlik M, Machkova N, Duricova D, et al. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF- α therapy during pregnancy: three-center study. *Scand J Gastroenterol*. 2013; 48(8): 951–958.
- Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med*. 2013; 369(8): 699–710.
- Moens A, van Hoeve K, Humblet E, et al. Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab. *J Crohns Colitis*. 2018.
- Mahadevan U, Vermeire S, Lasch K, et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. *Aliment Pharmacol Ther*. 2017; 45(7): 941–950.
- Rowan CR, Cullen G, Mulcahy HE, et al. Ustekinumab Drug Levels in Maternal and Cord Blood in a Woman With Crohn's Disease Treated Until 33 Weeks of Gestation. *J Crohns Colitis*. 2018; 12(3): 376–378.
- Lund T, Thomsen SF. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series. *Dermatol Ther*. 2017; 30(3).
- Vermeire S, Carbonnel F, Coulie PG, et al. Management of inflammatory bowel disease in pregnancy. *J Crohns Colitis* 2012; 6: 811–823.
- Zbořil V, a kol. *Idiopatické střevní záněty*. Praha: Mladá fronta, 2018.
- Mahadevan U, Martin CF, Chambers C, et al. Achievement of developmental milestones among off- spring of women with inflammatory bowel disease: The PIANO Registry. *Gastroenterology* 2014; 146: S–1.
- Bortlik M, Ďuricová D, Douda T, et al. Doporučení pro podávání biologické léčby pacientům s idiopatickými střevními záněty: čtvrté, aktualizované vydání. *Gastroent Hepatol* 2019; 73(1): 11–24.
- Nielsen O, et al. Safety of TNF- α inhibitors during IBD pregnancy: a systematic review. *BMC Med* 2013; 11: 174.
- Bortlik M, Ďuricová D, Kohout P, et al. Doporučení pro podávání biologické terapie u idiopatických střevních zánětů: třetí, aktualizované vydání. *Gastroent Hepatol* 2016; 70: 11–26.
- Bortlik M, Duricova D, Machkova N, et al. Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children. *Inflamm Bowel Dis* 2014; 20: 495–501.
- Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2013; 11(3): 286–292.
- Scherl E, Jacobstein D, Murphy C, et al. A109 Pregnancy outcomes in women exposed to ustekinumab in the Crohn's disease clinical development program. *J Canadian Association Gastroenterology* 2018; I(Suppl 2): 166.
- Julsgaard M, Kjeldsen J, Brock B, et al. Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease. *Aliment Pharmacol Ther* 2018; 48(3): 386–388.